The invention relates to the creation of hydrogels from poly-amino acids designed from β-aggregation-prone regions of functional amyloidogenic proteins. These designed peptides self-assemble into a three-dimensional nanofibril matrix, providing a robust and biocompatible scaffold for tissue engineering. The hydrogels can be used for 3D tumor models, enabling more accurate drug testing and dosage optimization. Additionally, these hydrogels serve as a depot for the controlled and sustained release of therapeutics and biologic agents, enhancing the efficacy of drug delivery systems. The technology offers a scalable, cost-effective solution with wide-ranging applications in biomedical fields.
- Tunable Physiochemical Properties: By modifying amino acids, the physiochemical properties of the hydrogel can be precisely tuned, enabling the engineering of various nanostructures for targeted drug delivery.
- 3D In Vitro Tumor Models: The hydrogels serve as scaffolds for creating 3D in vitro tumor models, providing a realistic environment for testing anticancer therapeutics and better simulating the native tumor microenvironment.
- Improved Drug Testing Platforms: These hydrogels provide a reliable platform for generating in vitro results that closely mimic in vivo conditions, enhancing the predictability and reliability of anticancer drug testing.
- Minimized Surgical Risks: The injectable nature of the hydrogels reduces the need for surgical delivery of scaffolds, thereby minimizing associated risks and improving patient outcomes.
- Compatibility with Various Cancer Cell Lines: The technology supports the development of 3D tumor models using any cancerous cell line, facilitating comprehensive drug testing from target identification to safety assessment.
It has shown efficient formation of cancer cell spheroids within 7 days, ranging from 50-300 μm. The technology enables the encapsulation of drugs like doxorubicin and trans-retinoic acid without chemical cross-linking, achieving controlled and sustained release for targeted therapeutic effects.
In a lab environment, successful in vitro tests have demonstrated 80% cancer cell death and neuronal differentiation. Cancer cell spheroids ranging from 50-300 μm were efficiently formed.
5
This technology has the potential to revolutionize biomedical applications by providing more effective and biocompatible materials for tissue engineering and regenerative medicine. It could significantly improve cancer treatment outcomes through better drug testing platforms and more efficient drug delivery systems, ultimately enhancing patient care and treatment efficacy.
Biotechnology, Pharmaceuticals, Medical Devices, Tissue Engineering, Regenerative Medicine
- Tissue Engineering and Regeneration: Provide scaffolds for cell adhesion and tissue growth, mimicking the natural extracellular matrix
- Biocompatible Drug Carriers: Reduce adverse immune responses due to their natural peptide composition
- Cancer Research: Facilitate the development of realistic in vitro 3D models for cancer research Implantable
- Medical Devices: Provide biocompatible coatings that reduce rejection and infection risks
- Injectable Hydrogels: Suitable for minimally invasive surgeries and treatments, as they can gel in situ
201921000523
455242